Camizestrant

Generic Name: Camizestrant

Clinical Trials

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Camizestrant
Drug: Midazolam
Drug: Carbamazepine

First Posted Date: 2024-08-09

Last Posted Date: 2025-04-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT06547164

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Phase 3

Recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Saruparib (AZD5305)
Drug: Camizestrant
Drug: Abemaciclib
Drug: Ribociclib
Drug: Palbociclib
Drug: Fulvestrant
Drug: Letrozole
Drug: Anastrozole
Drug: Exemestane

First Posted Date: 2024-04-24

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 500

Registration Number: NCT06380751

Locations: 🇬🇧
Research Site, Taunton, United Kingdom

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: High-grade Serous Ovarian Cancer (HGSOC)
ER+ HER2- Advanced Breast Cancer

Interventions: Drug: AZD8421
Drug: Camizestrant
Drug: Abemaciclib
Drug: Ribociclib
Drug: Palbociclib

First Posted Date: 2024-01-03

Last Posted Date: 2025-05-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 348

Registration Number: NCT06188520

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase 3

Recruiting

Conditions: Breast Cancer, Early Breast Cancer

Interventions: Drug: Tamoxifen
Drug: Camizestrant
Drug: Anastrozole
Drug: Abemaciclib
Drug: Letrozole
Drug: Exemestane

First Posted Date: 2023-07-19

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 5500

Registration Number: NCT05952557

Locations: 🇬🇧
Research Site, Whitchurch, United Kingdom

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Camizestrant

First Posted Date: 2023-03-30

Last Posted Date: 2025-03-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 22

Registration Number: NCT05790304

Locations: 🇸🇰
Research Site, Bratislava, Slovakia

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Phase 3

Recruiting

Conditions: Breast Cancer, Early Breast Cancer

Interventions: Drug: Tamoxifen
Drug: Camizestrant
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane

First Posted Date: 2023-03-20

Last Posted Date: 2025-05-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 4300

Registration Number: NCT05774951

Locations: 🇻🇳
Research Site, Hue, Vietnam

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Camizestrant
Drug: Itraconazole

First Posted Date: 2022-09-23

Last Posted Date: 2023-01-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT05551897

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AZD9833
Drug: Dabigatran Etexilate
Drug: Midazolam
Drug: Celecoxib
Drug: Omeprazole

First Posted Date: 2022-06-29

Last Posted Date: 2023-01-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 59

Registration Number: NCT05438303

Locations: 🇺🇸
Research Site, Berlin, New Jersey, United States

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Phase 3

Active, not recruiting

Conditions: ER-Positive HER2-Negative Breast Cancer

Interventions: Drug: AZD9833
Drug: AZD9833 Placebo
Drug: Anastrozole placebo
Drug: Anastrozole
Drug: Letrozole placebo
Drug: Letrozole
Drug: Palbociclib
Drug: Abemaciclib
Drug: Luteinizing hormone-releasing hormone (LHRH) agonist
Drug: Ribociclib

First Posted Date: 2021-07-16

Last Posted Date: 2025-01-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 315

Registration Number: NCT04964934

Locations: 🇬🇧
Research Site, Taunton, United Kingdom

AZD9833 China PK Study

Phase 1

Completed

Conditions: ER+, HER2-, Metastatic Breast Cancer

Interventions: Drug: AZD9833
Drug: AZD9833 with palbociclib
Drug: AZD9833 with everolimus

First Posted Date: 2021-03-26

Last Posted Date: 2024-12-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 28

Registration Number: NCT04818632

Locations: 🇨🇳
Research Site, Wuhan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.